Correction to: Alz Res Therapy 5, 32 (2013)
https://doi.org/10.1186/alzrt186
It has recently come to our attention that a paper we published in 2013 in Alzheimer’s Research & Therapy never included the tables (Tables 1, 2 and 3) and supplemental tables (Additional file 1) in the published manuscript [1]. This must have been an oversight at the proof or production stage.
Table 1.
Participants
| Controls | Probable Alzheimer’s Disease (AD) | ||||
|---|---|---|---|---|---|
| Case # | Age | MMSEa | Case # | Age | MMSEa |
| 1 | 75 | 28 | 1 | 83 | 20 |
| 2 | 72 | 29 | 2 | 77 | 18 |
| 3 | 74 | 30 | 3 | 90 | 11 |
| 4 | 67 | 29 | 4 | 83 | 20 |
| 5 | 73 | 29 | 5 | 82 | 24 |
| 6 | 60 | 30 | 6 | 61 | 12 |
| 7 | 69 | 30 | 7 | 55 | 25 |
| AVERAGES: | 70.00 | 29.3 | 75.86 | 18.6 | |
Cases in bold were pooled for proteomic analysis
Bold type-face indicates cases pooled for proteomic analysis
aMMSE mini mental status exam, clinical measurement of cognitive function
Table 2.
DAVID analysis of changes in proteins associated with platelet-specific secretion
| Mean log2 (AD/CT) |
R1 vs R2 CV, SD% |
Symbol | Protein Name | Ontology Groups |
|---|---|---|---|---|
| −1.70 | 0.6% | FGA | fibrinogen alpha chain | A, B, C, E, F |
| −2.03 | 7.5% | FGB | fibrinogen beta chain | A, B, C, E, F |
| −1.69 | 1.5% | FGG | fibrinogen gamma chain | A, B, C, E, F |
| −2.02 | 1.9% | VWF | von Willebrand factor | A, B, C, E |
| −1.23 | 39% | PROS1 | protein S (alpha) | B, C, E, F |
| −1.19 | 59% | FN1 | fibronectin 1 | B, C, D, F |
| −1.19 | 41% | SERPINA1 | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 | B, C, E |
| −1.47 | 31% | SPARC | secreted protein, acidic, cysteine-rich (osteonectin) | B, C, F |
| −2.05 | 0.9% | THBS1 | thrombospondin 1 | B, C, F |
| 1.47 | 1.2% | GP9 | glycoprotein IX (platelet) | B, C |
| −2.82 | 2.9% | C4BPA | complement component 4 binding protein, alpha | D, E |
| −1.24 | 94% | SERPINE1 | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | E, F |
| −1.83 | 66% | TF | transferrin | C |
| −1.65 | 10% | HP | haptoglobin-related protein; haptoglobin | D |
| −1.33 | 31% | SUSD1 | sushi domain containing 1 | D |
Table 3.
Overlap of AD platelet membrane protein changes with previously proposed mechanistic and diagnostic biomarkers
| Mean log2 (AD/CT) |
R1 vs R2 CV, SD% |
Symbol | Protein Name |
|---|---|---|---|
| 2.46 | 14% | MGAT4B | mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B |
| −1.23 | 52% | VPS13C | vacuolar protein sorting 13 homolog C (S. cerevisiae) |
| −1.24 | 20% | AGPS | alkylglycerone phosphate synthase |
| −1.92 | 15% | FTL | ferritin, light polypeptide |
| −1.97 | 7.0% | IGF1R | insulin-like growth factor 1 receptor |
Tables 1, 2 and 3 are shown below.
Supplementary Information
Additional file 1: Supplementary Table S1. 1009 proteins identified by unique peptides (top group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. Supplementary Table S2. 1957 total proteins (all potential group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. Supplementary Table S3. 144 potential marker proteins identified in platelet membrane proteome from a probable AD pool (FDR < 7%). Supplementary Table 4. 10 Classes incorporating 97 potentially novel AD biomarkers quantified in platelet membrane pools.
Contributor Information
Nicholas T. Seyfried, Email: nseyfri@emory.edu
James J. Lah, Email: jlah@emory.edu
Reference
- 1.Donovan LE, Dammer EB, Duong DM, et al. Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease. Alz Res Therapy. 2013;5:32. doi: 10.1186/alzrt186. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1: Supplementary Table S1. 1009 proteins identified by unique peptides (top group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. Supplementary Table S2. 1957 total proteins (all potential group members) identified in platelet membrane proteome from either a probable AD pool or a cognitive normal pool. Supplementary Table S3. 144 potential marker proteins identified in platelet membrane proteome from a probable AD pool (FDR < 7%). Supplementary Table 4. 10 Classes incorporating 97 potentially novel AD biomarkers quantified in platelet membrane pools.